PHAT
Phathom Pharmaceuticals, Inc.
$11.33
-0.25
(-2.16%)
Mkt Cap
903.63M
Volume
734,587
52W Range
3.92-18.31
Sector
Healthcare
Beta
0.57
EPS (TTM)
-2.12
P/E Ratio
-5.47
Revenue (TTM)
204.89M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175.11M | 55.25M | 682,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (221.25M) | (334.33M) | (201.59M) | (197.72M) | (143.88M) | (129.07M) | (209.74M) | (1.29M) |
| EPS | -3.03 | -5.29 | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Free Cash Flow | (166.78M) | (266.90M) | (139.21M) | (147.57M) | (148.78M) | (70.73M) | (61.76M) | (1.02M) |
| FCF / Share | -2.29 | -4.22 | -2.71 | -3.77 | -4.02 | -2.13 | -2.50 | -0.12 |
| Operating CF | (166.78M) | (266.77M) | (137.58M) | (146.53M) | (148.46M) | (69.69M) | (36.51M) | (1.02M) |
| Total Assets | 259.15M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M | 257.18M | 902,000 |
| Total Debt | 2.71M | 554.95M | 139.03M | 97.07M | 91.34M | 49.02M | 23.57M | 1.95M |
| Cash & Equiv | 129.97M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M | 243.76M | 879,000 |
| Book Value | (438.17M) | (253.58M) | (72.76M) | (74.81M) | 72.16M | 194.27M | 227.96M | (1.29M) |
| Return on Equity | N/A | N/A | N/A | N/A | -1.99 | -0.66 | -0.92 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M | 682,000 | 0 | 0 |
| Net Income | (30.37M) | (21.15M) | (29.97M) | (75.81M) | (94.32M) | (74.45M) | (85.58M) | (91.45M) | (82.85M) | (79.57M) | (43.24M) | (40.97M) |
| EPS | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 | -0.84 |
| Free Cash Flow | (15.65M) | (4.89M) | (14.14M) | (62.73M) | (84.95M) | (63.46M) | (63.49M) | (70.77M) | (69.06M) | (44.27M) | (32.85M) | (22.21M) |
| FCF / Share | -0.19 | -0.07 | -0.19 | -0.87 | -1.18 | -0.89 | -0.98 | -1.21 | -1.18 | -0.77 | -0.58 | -0.46 |
| Operating CF | (15.65M) | (5.00M) | (14.12M) | (62.73M) | (84.93M) | (63.46M) | (63.57M) | (70.72M) | (69.02M) | (43.80M) | (31.91M) | (22.20M) |
| Total Assets | 305.12M | 259.15M | 240.29M | 250.22M | 294.21M | 378.47M | 387.04M | 319.38M | 356.50M | 413.84M | 236.99M | 265.04M |
| Total Debt | 2.63M | 2.71M | 2.71M | 574.50M | 564.64M | 554.95M | 518.99M | 506.38M | 469.05M | 139.03M | 226.40M | 219.39M |
| Cash & Equiv | 180.90M | 129.97M | 135.16M | 149.57M | 212.31M | 297.26M | 334.68M | 276.24M | 322.23M | 381.39M | 213.68M | 248.85M |
| Book Value | (336.95M) | (438.17M) | (422.53M) | (405.83M) | (338.38M) | (253.58M) | (187.11M) | (233.83M) | (148.50M) | (72.76M) | (17.77M) | 17.60M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.33 |
PHAT News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target